Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P01275 (glucagon)
 26,492 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The efficacy of Buscopan in tubeless duodenography was tested in 48 patients using different routes of administration. The drug led to successful results in 77 to 85 per cent of patients in the dosage used (40 mg), the intravenous route proving the most efficient. The drug is considered superior to Probanthine and glucagon (Glucagon-Lilly) in view of its safety, low incidence of side-effects and efficacy. Follow-through examinations of the small bowel at 1 hour are possible in 33 per cent of patients, although 40 per cent have mild residual abnormalities only.
 ...
PMID:Hyoscine-N-butylbromide (Buscopan) as a duodenal relaxant in tubeless duodenography. 79 Aug 97

Double contrast examination of the stomach has a greater accuracy than conventional barium meal, especially in the diagnosis of minor gastric lesions. The use of a common drinking straw with a side-hole to introduce air simultaneously with the barium suspension after gastric emptying with metoclopramide and using short acting hypotonic agents like Buscopan and Glucagon provides a practical and effective simplified technique for double contrast examination of the oesophagus, stomach and duodenum.
 ...
PMID:Double contrast examination of the stomach. An improved technique. 87 Oct 88

Based upon the findings in over 1200 patients, technique, indication and validity of pharmacoradiology in examinations of esophagus, stomach, duodenum, small and large intestine are critically evaluated and summarized. Dosis, effects, side effects and contraindications of the mostly applied pharmaca (Buscopan, Pro-Banthine, Paspertin, Glucagon, Cholecystokinin and Caerulein) are listed. The value of pharmacoradiology of the gastrointestinal tract for clinical roentgenology is stressed.
 ...
PMID:[Present status of pharmacoradiology of the gastrointestinal tract (author's transl)]. 101 16

The effects of glucagon (1 mg i.v.) and hyoscine butylbromide (Buscopan 20 mg i.v.) and placebo on the visualization of the pyelocalyceal systems and ureters was compared in a routine urography with abdominal compression in a double-blind, randomized trial comprising 189 kidneys and ureters. The visualization of the ureters in the supine position was highly significantly better than in the prone. In the prone position the ureteral visualization with Buscopan was marginally significantly better than with placebo or glucagon. Otherwise, neither Buscopan nor glucagon improved the pyeloureteral visualization. However, with glucagon the pyelocalyceal visualization was highly significantly poorer than with placebo, and marginally significantly poorer than with Buscopan.
 ...
PMID:Urography with spasmolytics. 231 37

One hundred and fourteen patients attending for barium meal examination were randomly allocated to receive Buscopan (hyoscine N-butylbromide, Boehringer Ingelheim; 20 mg) or glucagon (0.5 mg) as paralysing agents, or sterile water as control. The radiographs were analysed with regard to (a) gastric and duodenal distension and coating and (b) early or delayed filling of the duodenum with barium, in order to assess claims that paralysing agents influence radiographic quality. It was found that both duodenal distension and coating were better with Buscopan and glucagon than with water but there was no difference between Buscopan and glucagon in producing these effects. Relaxants produced no significant effect on distension or coating of the stomach. Glucagon prolonged the time of some examinations but gave better visualisation of the stomach, which was less frequently obscured by contrast in the duodenum.
 ...
PMID:A comparison of paralysing agents in double-contrast barium meal examinations. 406 32

The number of intravenous injections of hyoscine-N-butylbromide (Buscopan) or glucagon required to maintain relaxation of the duodenum during endoscopic retrograde cholangiopancreatography (ERCP) were compared in a double blind trial of 55 patients. There was no significant difference in the number of injections. Serum amylase levels after the use of both relaxants were compared in 50 patients undergoing ERCP. No significant difference in the levels of hyperamylasaemia were found.
 ...
PMID:Buscopan or glucagon for endoscopic cannulation of ampulla of vater? 617 80

In 1958, Welin recommended the routine use of atropine before a barium enema to reduce mucus secretion and make the examination more comfortable. Currently, many radiologists believe that smooth-muscle spasmolysis is a useful adjunct during a barium enema and use such a spasmolytic agent. One survey found that spasmolytic agents were administered more frequently in 1987 than in 1976. The use of glucagon had increased 20% between 1976 and 1987. Among 34 foreign institutions responding to the survey, 37% used glucagon and 45% used scopolamine butylbromide (Buscopan). Nevertheless, it is still controversial whether spasmolytic agents play a significant role in the performance and interpretation of a barium enema. Some radiologists routinely use a spasmolytic agent; others do so only selectively.
 ...
PMID:The use of antispasmodic drugs during barium enemas. 819 92

The authors compared the effectiveness of hyoscine butylbromide (Buscopan) and glucagon in reducing bowel motion artifact during abdominal intra-arterial digital subtraction angiography. Sixty-six patients referred to the radiology department of a tertiary-care hospital for abdominal angiography between October 1989 and July 1992 consented to participate in the study. Diabetic patients receiving insulin and those with glaucoma were not considered for the study. The patients were assigned at random to receive either Buscopan (39 patients) or glucagon (27) intravenously before angiography. Images obtained at three stages during the procedure were reviewed independently by three experienced vascular radiologists who were blinded as to treatment group; images for nine patients in the Buscopan group and seven in the glucagon group were excluded because of breathing artifact or body movement. For each image the radiologists scored bowel motion in each section of a six-section grid. The bowel motion scores during early, middle and late arterial phases and the total scores for the two groups did not differ significantly (t-test). On the basis of these findings, the authors continue to use Buscopan because it is less expensive than glucagon.
 ...
PMID:Reduction of bowel motion artifact during digital subtraction angiography: a comparison of hyoscine butylbromide and glucagon. 819 68

The aim of this study was to introduce the true fast imaging with steady-state precession (FISP) sequence for MR enteroclysis and compare it with the already used T1-weighted fast low-angle shot (FLASH) sequence. Twenty-one patients underwent both MR and conventional enteroclysis. The MR enteroclysis examination was performed after administration of an iso-osmotic water solution through a nasojejunal catheter and the following sequences were included: (a) true FISP; and (b) 3D FLASH with fat saturation after intravenous injection of 20 mg Buscopan or 1 mg glucagon and 0.1 mmol/kg gadolinium chelates. The true FISP sequence provided images with significantly fewer motion artifacts, whereas 3D FLASH was less sensitive to susceptibility and chemical shift artifacts. The homogeneity of endoluminal opacification, wall conspicuity, and distention of the small bowel were very good to excellent and the two sequences presented no statistically significant differences here. True FISP provided significantly better overall image quality than did 3D FLASH. The true FISP sequence can provide good anatomic demonstration of the small bowel on T2-like images and could be combined with T1-weighted FLASH images for an integrated protocol of MR enteroclysis.
 ...
PMID:MR enteroclysis protocol optimization: comparison between 3D FLASH with fat saturation after intravenous gadolinium injection and true FISP sequences. 1141 61

The aim of this prospective study was to compare the intraindividual aperistaltic effect of 40 mg hyoscine N-butylbromide (HBB/Buscopan) with that of 1 mg glucagon on small bowel motility by using magnetic resonance imaging (MRI). Ten healthy volunteers underwent two separate 1.5-T MRI studies (HBB/glucagon) after a standardized oral preparation with an aqueous solution of Gd-DOTA and ispaghula (Metamucil). A 2D T1-w GRE sequence was acquired (TR 2.7 ms/TE 1.3 ms, temporal resolution 0.25 s) before and after intravenous (i.v.) drug administration and motility was followed over 1 h. On the resulting images the cross-sectional luminal diameters were assessed and plotted over time. Baseline motility frequency, onset of aperistalsis, duration of arrest, reappearance of motility and return to normal motility were analysed. Significant differences regarding reliability and duration of aperistalsis were observed. In the HBB group aperistalsis lasted a mean of 6.8 +/- 5.3 min compared with 18.3 +/- 7 min after glucagon (p < 0.0001). In 50% of cases HBB did not accomplish aperistalsis, whereas glucagon always succeeded (p = 0.05). There were no significant differences in terms of baseline and end frequencies for the onset of aperistalsis (22.2 +/- 37.5 s HBB/13.4 +/- 9.2 s glucagon, p = 0.1), nor for the return to normal motility. Arrest of small bowel motion is achieved more reliably and lasts significantly longer after i.v. administration of 1 mg glucagon compared with 40 mg HBB.
 ...
PMID:Aperistaltic effect of hyoscine N-butylbromide versus glucagon on the small bowel assessed by magnetic resonance imaging. 1919 Sep 16


1 2 Next >>